Ziftomenib: a menin inhibitor for R/R NPM1-mutated AML

Harry Erba, MD, PhD, Duke University, Durham, NC, comments on the activity, tolerability and resistance profile of ziftomenib as a single agent in NPM1-mutated relapsed/refractory acute myeloid leukemia (R/R AML), highlighting the efficacy and safety data from the Phase I/II KOMET-001 trial (NCT04067336). Dr Erba also discusses the mechanism of action of menin inhibitors, the activity of ziftomenib in KMT2A-rearranged AML, and the occurrence of resistance mutations against menin inhibitors. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.